Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and Low-dose Prednisone in Pulmonary Sarcoidosis
NCT05247554Phase 3Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2022
- Primary completion
- Mar 2023
01
Overview
Phase 3, randomised, open-label trial of hydroxychloroquine in pulmonary sarcoidosis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Forced Vital Capacity at 6 months. Status: unknown.
02
Drugs
hydroxychloroquine
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT05247554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247554.